MARKET

GRFS

GRFS

Grifols
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.69
+0.04
+0.18%
After Hours: 21.69 0 0.00% 16:00 11/15 EST
OPEN
21.65
PREV CLOSE
21.65
HIGH
21.77
LOW
21.63
VOLUME
600.25K
TURNOVER
--
52 WEEK HIGH
23.03
52 WEEK LOW
17.42
MARKET CAP
14.84B
P/E (TTM)
24.82
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GRFS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

GRFS News

  • Grifols introduces AlphaID, a free cheek swab to screen for Alpha-1, the most common genetic form of COPD
  • PR Newswire.11/07 15:00
  • Benzinga's Top Upgrades, Downgrades For October 28, 2019
  • Benzinga.10/28 13:58
  • Santander Upgrades Grifols to Buy
  • Benzinga.10/28 11:29
  • Is Grifols, S.A.'s (BME:GRF) ROE Of 12% Impressive?
  • Simply Wall St..10/14 06:22

More

Industry

Pharmaceuticals
+1.25%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Name
Price
%Change

About GRFS

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma for therapeutic use. The Hospital division offers non-biological pharmaceutical products and medical supplies for hospital pharmacy. The Diagnostic division provides clinical analysis and laboratory testing tools to laboratories, hospitals and blood banks. The Raw materials division includes sales of intermediate biological products, as well as manufacturing services to third parties. The Company operates production facilities in Spain, the United States, Mexico and Australia, among others. It controls numerous subsidiaries, such as Kiro Grifols SL.
More

Webull offers Grifols SA - ADR (GRFS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.